Frequency Therapeutics (Nasdaq:FREQ) - Aktienkurs, Nachrichten und Analyse

FREQ Aktienübersicht

As of November 3, 2023, Frequency Therapeutics, Inc.

FREQ fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Belohnungen

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 4.7% pro Jahr sinken.

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Hat weniger als 1 Jahr Cash Runway

Die Aktionäre wurden im vergangenen Jahr verwässert

+ 2 mehr Risiken

Frequency Therapeutics, Inc. Wettbewerber

Lexicon Pharmaceuticals

NasdaqGS:LXRX

US$657.9m

Allogene Therapeutics

NasdaqGS:ALLO

US$530.3m

Altimmune

NasdaqGM:ALT

US$433.2m

Sage Therapeutics

NasdaqGM:SAGE

US$722.2m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Frequency Therapeutics
Historical stock prices
Current Share Price	US$14.98
52 Week High	US$279.50
52 Week Low	US$9.15
Beta	0.77
1 Month Change	-0.10%
3 Month Change	-58.68%
1 Year Change	-87.52%
3 Year Change	-98.71%
5 Year Change	n/a
Change since IPO	-97.81%

Aktuelle Nachrichten und Updates

Recent updates

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

Jan 01

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Jan 19

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Aug 18

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

Jul 31

Frequency Therapeutics (FREQ) Investor Presentation - Slideshow

Jun 18

Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout

Apr 21

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

Apr 04

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

Mar 15

If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

Jan 22

Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Dec 27

Frequency Therapeutics to host investor event in early January next year

Dec 18

How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?

Dec 10

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 19

Frequency Therapeutics EPS beats by $0.16, beats on revenue

Nov 16

Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results

Nov 09

Aktionärsrenditen

	FREQ	US Biotechs	US Markt
7D	29.1%	0.1%	1.2%
1Y	-87.5%	7.1%	20.8%

Rendite im Vergleich zur Industrie: FREQ unter dem Niveau der Branche US Biotechs, die im vergangenen Jahr eine Rendite von 7.4% erzielte.

Rendite vs. Markt: FREQ hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is FREQ's price volatile compared to industry and market?
FREQ volatility
FREQ Average Weekly Movement	12.5%
Biotechs Industry Average Movement	10.3%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.9%

Stabiler Aktienkurs: FREQDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: FREQDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 21% auf 12% gesunken, liegt aber immer noch über 75 % der Aktien von US.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2014	47	David Lucchino	www.frequencytx.com

Frequency Therapeutics, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Frequency Therapeutics im Vergleich zum Marktanteil des Unternehmens?
FREQ grundlegende Statistiken
Marktanteil	US$547.27m
Gewinn(TTM)	-US$59.31m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-9.2x

Kurs-Gewinn-Verhältnis

Ist FREQ zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
FREQ Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$42.02m
Bruttogewinn	-US$42.01m
Sonstige Ausgaben	US$17.30m
Umsatz	-US$59.31m

Zuletzt gemeldete Gewinne

Sep 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.62
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich FREQ auf lange Sicht entwickelt?

Historische Performance und Vergleiche

FREQ Aktienübersicht

Belohnungen

Risikoanalyse

Frequency Therapeutics, Inc. Wettbewerber

NasdaqGS:LXRX

US$657.9m

NasdaqGS:ALLO

US$530.3m

NasdaqGM:ALT

US$433.2m

NasdaqGM:SAGE

US$722.2m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders.

Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders.

New major risk - Market cap size

Insufficient new directors

New major risk - Financial position

Frequency Therapeutics, Inc. Announces the Resignation of Christopher Loose as Chief Scientific Officer

Recent updates

Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders.

Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders.

New major risk - Market cap size

Insufficient new directors

New major risk - Financial position

Frequency Therapeutics, Inc. Announces the Resignation of Christopher Loose as Chief Scientific Officer

New major risk - Share price stability

Korro Bio, Inc. entered into a definitive merger agreement to acquire Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders in a reverse merger transaction.

Frequency Therapeutics, Inc. Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

Frequency Therapeutics, Inc. Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss

Price target decreased to US$6.67

Frequency Therapeutics, Inc. Completes Enrollment of Phase 2B Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Frequency Therapeutics, Inc.(NasdaqGS:FREQ) dropped from Russell 2500 Index

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Frequency Therapeutics, Inc., Annual General Meeting, Jun 21, 2022

Price target decreased to US$12.00

Insufficient new directors

Frequency Therapeutics, Inc. Announces Peter P. Pfreundschuh Stepping Down as Chief Financial Officer

Price target increased to US$14.33

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Insufficient new directors

Frequency Therapeutics, Inc. Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise

Frequency Therapeutics, Inc. Announces New FX-322 Results Showing that Additional Study Participants Gain Hearing Improvements at Later Time Points

Price target decreased to US$12.75

Consensus revenue estimates fall to US$36.2m

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Second quarter 2021 earnings released: US$0.52 loss per share (vs US$0.19 loss in 2Q 2020)

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

Lieff Cabraser Heimann & Bernstein, LLP Announces That Class Action Litigation Has Been Filed Against Frequency Therapeutics, Inc

Frequency Therapeutics, Inc.(NasdaqGS:FREQ) dropped from Russell 2500 Growth Index

Co-Founder exercised options to buy US$1.1m worth of stock.

Frequency Therapeutics (FREQ) Investor Presentation - Slideshow

Rosen Law Firm Encourages Frequency Therapeutics, Inc. Investors with Losses Exceeding $100,000 to Secure Counsel Before Important Deadline

Price target decreased to US$14.25

Consensus forecasts updated

Forecast to breakeven in 2025

Insider recently bought US$89k worth of stock

Consensus forecasts updated

First quarter 2021 earnings released: US$0.60 loss per share (vs US$0.16 loss in 1Q 2020)

Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

Full year 2020 earnings released: US$0.82 loss per share (vs US$2.29 loss in FY 2019)

Independent Director exercised options to buy US$316k worth of stock.

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

Co-­Founder exercised options and sold US$469k worth of stock

Frequency Therapeutics, Inc. Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322

New 90-day high: US$54.87

Frequency Therapeutics, Inc. Appoints Kevin Franck as Senior Vice President of Strategic Marketing and New Product Planning

Co-­Founder exercised options and sold US$385k worth of stock

New 90-day high: US$40.50

If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

Frequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing Officer

Co-­Founder exercised options and sold US$594k worth of stock

Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Independent Director recently sold US$1.7m worth of stock

Frequency Therapeutics, Inc. Enters into an Agreement for Termination of Lease and Voluntary Surrender of Premises

Co-Founder exercised options and sold US$469k worth of stock

Co-Founder exercised options and sold US$385k worth of stock

Co-Founder exercised options and sold US$594k worth of stock

Co-Founder exercised options and sold US$437k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Erträge & Einnahmen